Natural killer cells require selectins for suppression of subcutaneous tumors

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2531-2539

  Sobolev, Olga ^a,b   Stern, Patrick ^a   Lacy Hulbert, Adam ^a,c   Hynes, Richard O ^a,d  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; SELECTIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTERFERON PRODUCTION; LEWIS CARCINOMA; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL GROWTH; EXPERIMENTAL MELANOMA; EXPERIMENTAL NEOPLASM; FEMALE; IMMUNOLOGY; MALE; MOUSE MUTANT; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; CARCINOMA, LEWIS LUNG; CELL GROWTH PROCESSES; FEMALE; KILLER CELLS, NATURAL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; SELECTINS;

EID: 65549087656     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3126     Document Type: Article

References (50)

1. Dunn CR Bruce AT. Ikeda H. Old 1J, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
2. Soloski MJ. Recognition of tumor cells by the innate immune system Curr Opin Immunol 2001;13:151-62.
3. Dunn GP, Old LJ. Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2001:22: 329-60.
4. Stagg J. Johnstone RW. Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007;220:82-101.
5. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007:117:1137-46.
6. Vakkila I, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2001:4: 641-8.
7. Allavena P. Sica A, Garlanda C, Mantovani A. The Yin- Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008:222:155-61.
8. S. Conti P. Castellani ML. Kempuraj D. et al. Role of mast cells in tumor growth. Ann Clin Lab Sci 2007:37:315-22.
9. DeNardo DG, Coussens LM. Inflammution and breast adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007;9:212.
10. Lowe D, Jorizzo J, Hutt MS. Tumour-associated eosinophilia review. J Clin Pathol i9Sl;34:1343-8.
11. Kim R. Emi M, Tanabe K, Arihiro K. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 2007;121:149-57.
12. Diefenbach A. Jensen ER. Jamieson AM, Raulet DH. Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-71.
13. Cerwenka A. Baron JL. Lanier LL. Ectopic expression natural killer cell-mediated rejection of a MHC class 1-bearing tumor in vivo. Proc Natl Acad Sci USA 2001;9S: 11521-6.
14. Coussens LM. Werb Z, Inflammation and cancer. Nature 2002:420:860-7.
15. Mantovani A. Sozzani S. Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002:23:549-55.
16. Smyth MJ. Hayakawa Y, Takeda K. Yugita H. New-aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-61.
17. Smyth MJ, Swann J, Hayakawa Y. Innate tumor immune surveillance. Adv Exp Med Biol 2007:590:103-11.
18. Takeda K. Akira S. Roles of Toll-like receptors in innate immune responses. Genes Cells 2001;6:733-42.
19. Cooper MA. Fehniger TA. Fuchs A. Colonna M. Caligiuri MA, NK cell and DC interactions. Trends Immunol 2004;25:47-52.
20. Kalinski P, Giermasz A, Nakamura Y. et al. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 2005:42:535-9.
21. Martin-Fontecha A, Thomsen LL, Brett S, et al. Induced recruitment of NK cells to lymph nodes provides IFN-γ for 1(H) 1 priming. Nut Immunol 2004; 5:1260-5.
22. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nut Rev Immunol 2007:7:329-39.
23. Woan K, Reddy V. Potential therapeutic role of natural killer cells in cancer. Expert Opin Biol Ther 2007; 7:17-29.
24. Gregoire C. Chasson L. Luci C, et al. The trafficking of natural killer cells. Immunol Rev 2007:220:169-82.
25. Morris MA. Ley K. Trafficking of natural killer cells. Curr Mol Med 2004;4:431-8.
26. Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol 2004;22:129-56.
27. Sperandio M. Selectins and glycosyltransferases in leukocyte rolling in vivo. FERS J 2006;273:4377-89.
28. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999:79:181-213.
29. Mayadas TN, Johnson RC, Rayburn H. Hynes RO. Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993:74:541-54.
30. Arbones ML. Ord DC, Ley K. et al. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice, immunity 1994;1:247-60.
31. Frenette PS, Mayadas TN, Rayburn H, Hynes RO, Wagner DD. Double knockout highlights value of endothelial selectins. Immunol Today 1996:17:205.
32. Robinson SD, Frenette PS. Rayburn H, et al. Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte recruitment. Proc Natl Acad Sci U S A 1999:96:11452-7.
33. 5- integrins or selectins, Proc Natl Acad Sci U S A 2004;101:763-8.
34. Kim S. lizuka K, Aguila HL, Weissman IL, Yokoyama WM, In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 2000:97:2731-6.
35. Shinkai Y. Rathhun G. Lam KP, et al. RAG-2-deficient initiate V(D)J rearrangement' Cell 1992;68:S55-67.
36. Borsig L, Wong R, Hynes RO, Varki NM. Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis, Proc Natl Acad Sci U S A 2002;99:2193-8.
37. Yokoyama WM. Kim S. Analysis of individual natural killer cell responses. Methods Mol Biol 200S; 115:179-96.
38. Tanaka T, Kitamura F. Nagasaka Y. Kuida K. Suwa H, Miyasaka M, Selective long-term elimination of natural killer cells in viva by an anti-interleukin 2 receptor β chain monoclonal antibody in mice. J Exp Med 1993:178: 1103-7.
39. Kleinman HK, McGarvey ML, Hassell JR. el al. Basement membrane complexes with biological activity. Biochemistry 1986;35:312-8.
40. Kleinman HK. McGarvey ML, Liotta LA, Robey PG, Tryggvason K Martin GR. isolation and characterization of type ÏV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982; 21:6188-93.
41. Andre P. Spertini O, Guia S, et al. Modification of P-selectin glycoprotein ligand-1 with a natural killer ligand for L-selectin. Proc Natl Acad Sci U S A 2000:97: 3400-5.
42. Frey M, Packianathan NB. Fehniger TA. et al. Differential expression and function of L-selectin on Cl)56bright and CD56dim natural killer cell subsets. J Immunol 1998:161:400-8.
43. Uksila J. Salmi M, Butcher EC, Tarkkanen J, Jalkanen S. Function of lymphocyte homing-associated adhesion molecules on human natural killer and lymphokine-aclivated killer cells. J Immunol 1997;158:1610-7.
44. Yokoyama WM. Kim S. French AR. The dynamic life of natural killer cells. Annu Rev Immunol 2004:22:405- 29.
45. Loza MJ. Zamai L. Azzoni L, Rosati E. Perussia B. Expression of type 1 (interferon γ) and type 2 stages of natural killer cell differentiation from progenitor cells. Blood 2002:99:1273-81.
46. Kim S. Song YJ, Higuchi DA. et al. Arrested natural killer cell development associated with transgene insertion into the Atf2 locus. Blood 2006;107:1024-30.
47. + regulatory T cells. J Leukoc Biol 2007;81:144-53.
48. Yamada M. Yanaba K, Hasegawa M. et al. Regulation mechanisms by L-selectin and intercellular adhesion molecule-1. Clin Exp Immunol 2006;143:216-27.
49. Lavergne E. Combadiere B. Bonduelle O, et al. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 2003;63:7468-71.
50. Chen S. Kawashima H, Lowe JB. Lanier LL. Fukuda M. Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J Exp Med 2005;202:1679-89.